

Oxford Medical Products has developed a safe, flexible, strong and durable hydrogel, surviving the harsh conditions of the stomach for up to 7 days.





Scan for poster & audio




(1) Background

- Increasing levels of obesity worldwide highlight the need for novel interventions to promote weight management.
- An ingestible, gastroretentive, degradable, double-network superporous hydrogel has been developed, to elicit feelings of satiety and reduce food intake.


(2) Mode of action



(3) Pre-clinical testing



(4) Clinical trials



- Phase 1/2a, first-in-human trial underway in the UK.
- Over 60 hydrogels taken in Phase 1.
- Participants reported appetite suppression and tolerability
- Some participants experienced nausea after dosing.
- Phase 3 starting approx. end of 2024.

Scan for Pre-registration



(5) In-human MRI data




Fig. 7: T1-weighted MRI (VIBE) approx. 2hrs after dosing 3 pills (indicated with arrows) with 250ml water (a) depicts 3D imaging plane; (b) axial view, (c) coronal view, (d) sagittal view through stomach (shown with yellow line).





Fig. 8: shMOLLI MRI approx. 2 hrs after dosing 3 pills with 250ml water, axial view of hydrogel (highlighted with white arrow) in stomach (dotted line).

Fig. 9: shMOLLI MRI 5 days after dosing (as above), axial view of hydrogel (highlighted with white arrow) in pylorus/upper duodenum.

- MRI on 3T Siemens Prisma
- Hydrogel visualised using T1-weighted VIBE and shMOLLI images up to 7 days after dosing.



Excellent biocompatibility:

All biological evaluation tests were performed in compliance with Good Laboratory Practice and ISO 10993 series.

Contact Elanor Hinton, Clinical Studies Manager, to register an interest as a site for our upcoming Phase 3 trial



¹ Oxford Medical Products Limited, Witney Business and Innovation Centre, Windrush Park Road, Witney, OX29 7DX, UK. ² Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK. ³ University Hospital Southampton, Southampton General Hospital, Tremona Road, Southampton, Hampshire, SO16 6YD, UK.